苯达莫司汀、利妥昔单抗和硼替佐米治疗复发/难治性华氏巨球蛋白血症的疗效与安全性:2期单臂FIL-BRB试验结果
这项多中心2期单臂FIL-BRB试验在38例有症状的复发/难治性华氏巨球蛋白血症患者中评估苯达莫司汀、利妥昔单抗和硼替佐米联合方案(每28天6周期),总缓解率84.6%,18个月无进展生存率84.2%,50%患者出现3-4级血液学毒性,主要为血小板减少。
要点
- 总缓解率84.6%,含11%完全缓解、39%非常好的部分缓解、32%部分缓解。
- 18、24、30个月无进展生存率分别为84.2%、81.5%、78.8%,18个月总生存率92.1%。
- 50%患者出现3-4级血液学毒性(主要为血小板减少),1-3级神经病变约10%。
核心结论
- BRB方案作为二线治疗对复发/难治性华氏巨球蛋白血症患者是有效且耐受性良好的挽救治疗。
- MRD监测显示该方案在清除残留病灶方面有较好疗效。
研究设计与样本
- 多中心2期单臂研究(Fondazione Italiana Linfomi FIL-BRB试验),纳入38例有症状的复发/难治性华氏巨球蛋白血症患者。
- 治疗方案:苯达莫司汀90 mg/m2第1-2天,利妥昔单抗375 mg/m2静脉第1天,硼替佐米1.3 mg/m2皮下第1、8、15、22天,每28天重复,共6周期。
- 在21例患者中,于基线和治疗结束时采用微滴数字聚合酶链反应(ddPCR)检测MYD88L265P和CXCR4S338X突变。
主要发现
- 治疗结束时总缓解率为84.6%,其中完全缓解4例(11%)、非常好的部分缓解15例(39%)、部分缓解12例(32%),按IWWM疗效标准评估。
- 18、24和30个月无进展生存率分别为84.2%(95%CI 68.2%-92.6%)、81.5%(95%CI 65.1-90.7)和78.8%(95%CI 62.0-88.8)。
- 18个月总生存率为92.1%(95%CI 77.5%-97.4%)。
- 19例患者(50%)发生3-4级血液学毒性,主要为血小板减少;1-3级神经病变发生率约10%,需降低硼替佐米剂量但未导致治疗中断。
- BRB治疗在治疗结束时诱导了高比例的分子学微小残留病(MRD)检测不到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m2 on days 1-2), rituximab (375 mg/m2 intravenously on day 1) and bortezomib (1.3 mg/m2 sc on days 1, 8, 15, 22) every 28 days for six cycles in 38 symptomatic patients with relapsed/refractory Waldenstrom macroglobulinaemia (RR-WM). Moreover, MYD88L265P and CXCR4S338X mutations were tested by droplet digital polymerase chain reaction (ddPCR) both at baseline and at the end of treatment in 21 patients. Overall response rate at the end of therapy was 84.6%, including 4 (11%) complete remission, 15 (39%) very good partial response, 12 (32%) partial responses according to IWWM response criteria. At 18, 24 and 30 months, progression-free survival was 84.2% (95% CI 68.2%-92.6%), 81.5% (95%CI 65.1-90.7) and 78.8% (95%CI 62.0-88.8) respectively. At 18 months, the Overall survival was 92.1% (95%CI 77.5%-97.4%). Overall, 19 patients (50%) experienced grade 3-4 haematological toxicity, mainly thrombocytopenia, and grade 1-3 neuropathy rate was about 10% and required bortezomib dose reduction but did not result in treatment interruption. Moreover, BRB treatment induced the high rates of undetectable molecular minimal residual disease (MRD) at the end of the therapy. BRB regimen used as second line is an effective and well-tolerated salvage treatment for relapsed refractory Waldenstrom macroglobulinaemia patients. MRD monitoring showed promising efficacy in clearing the residual disease.
引用
- Benevolo G, Drandi D, Villivà N, et al. Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial. Br J Haematol. 2024. PMID: 39604169. doi:10.1111/bjh.19920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。